Long-Term Effects of a Comprehensive Intervention Strategy for Salt Reduction in China: Scale-Up of a Cluster Randomized Controlled Trial
- PMID: 39683487
- PMCID: PMC11643943
- DOI: 10.3390/nu16234092
Long-Term Effects of a Comprehensive Intervention Strategy for Salt Reduction in China: Scale-Up of a Cluster Randomized Controlled Trial
Abstract
Salt intake in China was high and a series of salt reduction measures were accordingly carried out recently. Our study aimed to assess the long-term effect of a scale-up community randomized controlled trial (RCT); Methods: Individuals between the ages of 18 and 75, from six provinces in China, were recruited and randomized into control (n = 1347) and intervention (n = 1346) groups. A one-year salt reduction intervention was first implemented in the intervention group, followed by a two-year scale-up intervention in both groups. The 24 h urine sample, anthropometric measurement, and knowledge, attitude, and practice (KAP) of salt reduction, as well as lifestyle information, were collected at baseline, after one-year RCT (mid-term evaluation, n = 2456), and two-year scale-up intervention (terminal evaluation, n = 2267); Results: Both control (351.82 mg/24 h, p < 0.001) and intervention (192.84 mg/24 h, p = 0.006) groups showed a decrease in 24 h urinary sodium excretion from baseline to terminal evaluation. Except for an increase in 24 h urinary potassium excretion (85.03 mg/24 h, p = 0.004) and a decrease in systolic blood pressure (SBP) (2.95 mm Hg, p < 0.001) in the intervention group at the mid-term assessment, no statistically significant differences in other indicators were found between two groups. The KAP of salt reduction in two groups was gradually improved; Conclusions: After one-year RCT and two-year scale-up, all participants showed a decreasing trend in 24 h urinary sodium excretion and an increase in salt reduction KAP. The community salt reduction intervention package has the potential for broader application across other regions in China.
Keywords: 24 h urinary sodium excretion; China; randomized trial; salt reduction.
Conflict of interest statement
The authors declare no conflicts of interest. Feng J. He is an unpaid member of Action on Salt and World Action on Salt, Sugar and Health (WASSH).
Figures
Similar articles
-
Association of a Province-Wide Intervention With Salt Intake and Hypertension in Shandong Province, China, 2011-2016.JAMA Intern Med. 2020 Jun 1;180(6):877-886. doi: 10.1001/jamainternmed.2020.0904. JAMA Intern Med. 2020. PMID: 32338717 Free PMC article.
-
A self-monitoring urinary salt excretion level measurement device for educating young women about salt reduction: A parallel randomized trial involving two groups.J Clin Hypertens (Greenwich). 2019 Jun;21(6):730-738. doi: 10.1111/jch.13545. Epub 2019 May 6. J Clin Hypertens (Greenwich). 2019. PMID: 31058457 Free PMC article. Clinical Trial.
-
A town level comprehensive intervention study to reduce salt intake in China: protocol for a cluster randomised controlled trial.BMJ Open. 2020 Jan 9;10(1):e032976. doi: 10.1136/bmjopen-2019-032976. BMJ Open. 2020. PMID: 31924637 Free PMC article. Clinical Trial.
-
Effect of salt reduction interventions in lowering blood pressure in Chinese populations: a systematic review and meta-analysis of randomised controlled trials.BMJ Open. 2020 Feb 17;10(2):e032941. doi: 10.1136/bmjopen-2019-032941. BMJ Open. 2020. PMID: 32071177 Free PMC article.
-
Salt and blood pressure in community-based intervention trials.Am J Clin Nutr. 1997 Feb;65(2 Suppl):661S-670S. doi: 10.1093/ajcn/65.2.661S. Am J Clin Nutr. 1997. PMID: 9022562 Review.
References
-
- Li K.C., Huang L., Tian M., Di Tanna G.L., Yu J., Zhang X., Yin X., Liu Y., Hao Z., Zhou B., et al. Cost-Effectiveness of a Household Salt Substitution Intervention: Findings from 20 995 Participants of the Salt Substitute and Stroke Study. Circulation. 2022;145:1534–1541. doi: 10.1161/CIRCULATIONAHA.122.059573. - DOI - PubMed
-
- GBD 2021 Risk Factors Collaborators Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2162–2203. doi: 10.1016/S0140-6736(24)00933-4. - DOI - PMC - PubMed
-
- GBD 2021 Diseases and Injuries Collaborators Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133–2161. - PMC - PubMed
-
- Zhou M., Wang H., Zeng X., Yin P., Zhu J., Chen W., Li X., Wang L., Wang L., Liu Y., et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394:1145–1158. doi: 10.1016/S0140-6736(19)30427-1. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical